Table 8.

NMBA treatment (defined by > 3 days within 48 h from commencement of mechanical ventilation) vs controls on 90-day in-hospital mortality

	Propensity score-matched cohort (N = 324)
90-day mortality from ICU admission	Control (N = 162)	NMBA treatment (N = 162)	Total (N = 362)
Survived	130 (80.3%)	81 (50.0%)	211 (65.1%)
Died	32 (19.8%)	81 (50.0%)	113 (34.9%)
Total	162	162	324

Prior to propensity score matching, neuromuscular blocking agent (NMBA) treatment, defined as more than 3 days of continuous use of NMBAs, within 48 h from commencement of invasive mechanical ventilation, was associated with 90-day mortality (unadjusted Cox regression; HR 2.57, 95% CI 2.02, 2.71, p < 0.001). After propensity score matching, 372 patients who received NMBA treatment were matched with 372 controls (using replacement). Using the propensity score-matched cohort and adjusting for covariates as per Table 4, NMBA therapy was associated with 90-day mortality (adjusted HR 1.73, 95% CI 1.27, 2.37, p = 0.001)